Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis
Conditions
Interventions
Ixazomib
Cyclophosphamide
+1 more
Locations
3
United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
Start Date
June 12, 2017
Primary Completion Date
September 20, 2022
Completion Date
September 20, 2022
Last Updated
September 29, 2022
NCT06383143
NCT06192979
NCT07250269
NCT06022939
NCT04839003
NCT05066607
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions